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nterferons, naturally occuring glycoproteins with
molecular weights of approximately 20,000 dal-
tons, possess antiviral, antiproliferative, and im-
mune-stimulating properties. They are classified
into 3 antigenically distinct forms that are derived
from different cell types. Alpha (or) interferons are
derived from leukocytes, beta ([3) interferons from
fibroblasts, and gamma (/) interferons from T lym-
phocytes. They have been approved for use in the
treatment of condylomata acuminata, hepatitis B
and C, and hairy-cell leukemia.
While naturally occurring ot interferons can be
obtained from pooled leukocytes derived from
whole blood and then stimulated to produce inter-
feron [or-n3 Alferon (Purdue Frederick Com-
pany, Norwalk, CT); or-N1 WellferonTM (Pacific
Pharmacy, San Francisco, CA)], they can also be
produced through recombinant DNA technology
[o-2a RoferonT= (Roche Laboratories, Nutley,
NJ); ot-2b Intron A (Schering Corporation,
Kenilworth, NJ)]. ot-2a and ot-2b differ by only
amino acid in position -23. The natural interferons
are really mixtures of 14 or more types, while the
recombinant types are pure quantities of a single
species of interferon.
MECHANISM OF ACTION
As indicated above, interferons are antiviral, anti-
proliferative, and immune-stimulating. The mecha-
nism by which interferons block viral replication is
by inducing more than 24 different cellular proteins
that degrade viral RNA and interfere with viral pro-
tein synthesis. The antiproliferative activity of in-
terferons has been utilized in slowing the growth
of tumor cells. This cytostatic effect is achieved by
a modulation of the levels of cellular 2’,5’-oligoade-
nylate synthetase and of cell oncogenes such as
c-myc, c-fos, and c-H-ras. The immune-stimulating
properties contribute to the antiviral and antitumor
activities by enhancing the expression of cell sur-
face antigens, such as major histocompatibility com-
plex antigens. Interferons contribute to the lysis of
virus-infected and tumor cells by activating macro-
phages, natural killer cells, and cytotoxicT lympho-
cytes, as well as by cytokine induction.
PHARMACOKINETICS
The intramuscular administration of interferon pro-
duces peak plasma concentrations in 4-8 h. The
elimination half-life is between 2 and 3 h. How-
ever, the physiologic half-life may extend far be-
yond this time. Little is known of the pharmacoki-
netics of the intralesional (intradermal) or topical
administration. The activity is expressed in interna-
tional units (I.U.) and vials containing 3, 5, 10, 25,
and 50 million I.U. of recombinant interferon are
commercially available. Once reconstituted with
bacteriostatic water for injection, it is stable for
month if refrigerated. Natural interferons
(Alferon=) are available in 5 million I.U. vials which
are stable for 6 months if kept refrigerated. An 0.1
ml quantity (usually million units) is injected in-
tradermally with a number 30 needle into the base
of each lesion 2-3 times weekly. An intradermal
injection is performed in a similar manner to a puri-
fied protein derivative (PPD) injection. For intra-
muscular administration, usually 3 million I.U. is
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injected either "regionally" into the anterior thigh
or "systemically" into the deltoid muscle.
SIDE EFFECTS
The most commonly reported side effects are flu-
like symptoms including myalgias, headache, fever,
chills, nausea, and fatigue. Transient leukopenia,
occasional thrombocytopenia, and clinically insig-
nificant abnormalities of liver function tests all
readily reverse with discontinuation oftherapy. The
development of antibodies to interferon in 1% of
the recipients appears to have no clinical signifi-
cance. The flu-like side effects are reduced by lim-
iting the total dose to 3 or, at most, 5 million I.U.
per day and prophylactically administering acet-
aminophen immediately prior to therapy and again
6 h later when the chills and fever tend to occur.
Another helpful technique is to administer the in-
terferon late in the day, about 5 P.M. Since the chills
and fever occur 6 h later, the patient can go to bed
as usual and awaken in the morning free of side
effects. With the subsequent administration of in-
terferon, tachyphylaxis occurs with a lessening or
disappearance of symptoms (except fatigue) by the
second week. Interferon is contraindicated in
pregnancy.
SPECTRUM OF ANTIVIRAL ACTIVITY
Interferons, although they have no direct antiviral
activity in vitro, stimulate cells of the immune sys-
tem to develop antiviral activity and to produce
antiviral substances. Interferons have a broad spec-
trum of antiviral activity with proven in vivo activity
against human papillomavirus (HPV), hepatitis B
and C viruses, the herpes virus group (herpes sim-
plex, herpes zoster, cytomegalovirus), influenza vi-
rus, and human immunodeficiency virus. Within
the HPV group, clinically equipotent activity has
been demonstrated against the common anogenital
HPV types 6, 11, 16, and 18.
CLINICAL APPLICATIONS
Intralesionally injected interferon has demon-
strated clinical efficacy in the treatment of condylo-
mata acuminata in randomized, placebo-controlled,
double-blind clinical trials. 3’4 However, its clinical
usefulness is limited by several factors. First, while
it cures up to 70% of the warts that are refractory
to conventional therapy (laser, electrodesiccation,
cryotherapy, curettage, trichloroacetic acid, podo-
phyllotoxin, and 5-fluorouracil), approximately 25%
ofthe "cured" warts recur,3’4 undoubtedly due to the
persistence of HPV in the adjacent normal tissue.
Second, the intralesional injection twice or thrice
weekly is a cumbersome, labor-intensive method
of administration that is not adaptable to cervical
or vaginal disease. Two alternative approaches cir-
cumvent these limitations: 1) topical application of
interferon or an interferon inducer and 2) regional
or systemic administration of interferon.
After an early successful trial, topical interferon
administration has not proved effective, although
recent work using the topically applied imiquimod,
a heterocyclic amine that induces interferon pro-
duction in peripheral blood mononuclear cells, has
demonstrated efficacy in a placebo-controlled, dou-
ble-blind trial. The potential usefulness of a topical
application in the treatment of cervical or vaginal
disease and its lack of any systemic side effects
make this compound an interesting one suitable for
further clinical trials.
Regional (in the anterior thigh) or systemic (in
the deltoid muscle) administration of interferon has
been demonstrated to be effective in the treatment
of hepatitis B and C (50% and 25% cure rates, re-
spectively). However, it has not shown as much
efficacy in the treatment of anogenital HPV infec-
tions. The cure rates of the systemic administration
of interferons to treat condylomata acuminata have
been disappointingly low. Adjuvant therapy with
systemic interferon did not increase the efficacy of
cryotherapy in eradicating condylomata acuminata
either during or following treatment.9’1 However,
in 2 randomized trials, when interferon was admin-
istered regionally in the anterior thigh, it increased
the efficacy of laser therapy in treating vulvar con-
dylomata acuminata. 11’12 Why a discrepancy exists
between laser therapy and cryotherapy when inter-
feron is used as an adjuvant chemotherapy is un-
clear. It may have to do with the ability of the
laser to eradicate the viral reservoir in the adjacent
normal tissue. Alternatively, it may reflect the possi-
ble efficacy of the regional route (in the anterior
thigh) compared with systemic administration (in
the deltoid muscle) of interferon.
Systemic interferon therapy did not eliminate
HPV DNA or reduce the amount of DNA present
when genital warts were treated systemically with
o interferon. 13’14 Similarily, ot interferon failed to
eliminate HPVDNA from laryngeal papillomas that
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were treated systemically with interferon, is Further-
more, neither 13 interferon nor ot interferon has
shown greater efficacy when systemically adminis-
tered as an adjuvant to cryotherapy.
16 Additionally,
these interferons are less effective in the treatment
of HIV-positive individuals, who have an especially
high relapse rate. 17 These results suggest that sys-
temically administered interferons work mainly as
antiproliferative agents and have not yet fulfilled
their antiviral and immune-stimulating potentials
in the case of HPV infection.
COST
A 3 million I.U. vial, enough for a single treatment,
costs $31.50 (wholesale price). However, this cost
does not include the cost of administering the inter-
feron. It has been calculated to cost approximately
$1,500 for a course of therapy including the cost
of administration.6’9 Purchasing interferon in larger
quantities such as 5 million ($52.50), 10 million
($105), or 18 million ($189) I.U. vials does not re-
duce the cost.
SUMMARY
Interferons are useful in treating recalcitrant or re-
current warts, but are certainly not first-line therapy.
The intralesional administration is effective but lim-
ited to vulvar and penile disease. Regional adminis-
tration in the anterior thigh may be useful as an adju-
vant to superficial laser vulvectomy. Interferons
have not been shown to have a systemic effect on
anogenital warts when used either as primary ther-
apy or as an adjuvant to cryotherapy. They have not
been shown to reduce HPVDNA following systemic
therapy. In early trials, a topical interferon inducer,
imiquimod, appeared to be effective without sys-
temic side effects. This form may also be useful in
the treatment of vaginal and cervical disease.
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